Abstract
Alkamides are the major lipophilic constituents of Echinacea angustifolia roots. Due to their structural similarity with anandamide, we have evaluated their
ability to bind to rodent cannabinoid receptors CB1 and CB2 by a standard receptor
binding assay using [³H]CP-55,940 as a radioligand. The alkamides exhibited selective
affinity especially to CB2 receptors and can therefore be considered as CB ligands.
Most of the alkamides showed good metabolic stability as indicated by the similarity
between affinity to CB1 determined in the presence/absence of the protease inhibitor
PMSF. It is suggested that CB2 interactions may be the molecular mode of action of
Echinacea alkamides as immunomodulators.
Abbreviations
CB1:cannabinoid receptor 1
CB2:cannabinoid receptor 2
FAAH:Fatty acid amidohydrolase
PMSF:phenylmethanesulfonylfluoride
AEA:arachidonylethanolamide, anandamide
AA:arachidonic acid
IL:interleukin
MCP:monocyte chemoattractant protein
BSA:bovine serum albumin
TNF-α:tumor necrosis factor-alpha
MAPK:mitogen-activated protein kinase
JNK:jun N-terminal kinase
cAMP:cyclic adenosine monophosphate
CREB-1:responsive element binding protein-1
ATF-2:activating transcription factor-2
NF-κB:nuclear factor kappa B
Tris:Tris-(hydroxymethyl)-amino-methane
CP55940:(-)-cis-3-[2-hydroxy-4(1,1-dimethyl-heptyl)phenyl]-trans-4-(3-hydroxypropyl)cyclohexanol
References
- 1 Bauer R, Wagner H.
Echinacea species as potential immunostimulatory drugs. In: Wagner H, Farnsworth NR, editors
Economic and Medicinal Plant Research. London; Academic Press 1991: pp 253-321
- 2 Bauer R. Chemistry, analysis and immunological investigations of Echinacea phytopharmaceuticals. In: Wagner H, editor Immunomodulatory Agents from Plants Basel;
Birkhäuser Verlag 1999: pp 41-88
- 3
Bauer R, Remiger P, Wagner H.
Alkamides from the roots of Echinacea angustifolia
.
Phytochemistry.
1989;
28
505-8
- 4
Gertsch J, Schoop R, Kuenzle U, Suter A.
Echinacea alkylamides modulate TNF-α gene expression via cannabinoid receptor CB2 and multiple
signal transduction pathways.
FEBS Lett.
2004;
577
563-9
- 5 Remiger P. Zur Chemie und Immunologie neuer Alkylamide und anderer Inhaltsstoffe
aus Echinacea purpurea, Echinacea angustifolia und Echinacea pallida
. PhD thesis University of Munich; 1988
- 6
Lan R, Liu Q, Fan P, Lin S, Fernando S R, McCallion D. et al .
Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists.
J Med Chem.
1999;
42
769-76
- 7
Cheng Y C, Prusoff W H.
Relationship between the inhibition constant (Ki) and the concentration of inhibitor
which causes 50 per cent inhibiton (IC50) of an enzymatic reaction.
Biochem Pharmacol.
1973;
22
3099-108
- 8
Lang W, Qin C, Hill W A, Lin S, Khanolkar A D, Makriyannis A.
High-performance liquid chromatographic determination of anandamide amidase activity
in rat brain microsomes.
Anal Biochem.
1996;
238
40-5
- 9
Pertwee R G, Fernando S R, Griffin G, Abadji V, Makriyannis A.
Effect of phenylmethylsulphonyl fluoride on the potency of anandamide as an inhibitor
of electrically evoked contractions in two isolated tissue preparations.
Eur J Pharmacol.
1995;
272
73-8
- 10
Matias I, Pochard P, Orlando P, Salzet M, Pestel J, Di Marzo V.
Presence and regulation of the endocannabinoid system in human dendritic cells.
Eur J Biochem.
2002;
269
3771-8
- 11
Pertwee R G.
Pharmacology of cannabinoid CB1 and CB2 receptors.
Pharmacol Ther.
1997;
74
129-80
- 12
Klein T W, Newton C, Friedman H.
Cannabinoid receptors and immunity.
Immunol Today.
1998;
19
373-81
- 13
Goutopoulos A, Makriyannis A.
From cannabis to cannabinergics new therapeutic opportunities.
Pharmacol Ther.
2002;
95
103-17
- 14
Lin S, Khanolkar A D, Fan P, Goutopoulos A, Qin C, Paphadjis D. et al .
Novel analogues of arachidonylethanolamide (anandamide): Affinities for the CB1 and
CB2 cannabinoid receptors and metabolic stability.
J Med Chem.
1998;
41
5353-61
- 15
Jbilo O, Derocq J M, Segui M, Fur G L, Casellas P.
Stimulation of peripheral cannabinoid receptor CB2 induces MCP-1 and IL-8 gene expression
in human promyelocytic cell line HL60.
FEBS Lett.
1999;
448
273-7
- 16
Sugiura T, Oka S, Gokoh M, Kishimoto S, Waku K.
New perspectives in the studies on endocannabinoid and cannabis: 2-arachidonoylglycerol
as a possible novel mediator of inflammation.
J Pharmacol Sci.
2004;
96
367-75
- 17
Kishimoto S, Kobayashi Y, Oka S, Gokoh M, Waku K, Sugiura T.
2-Arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces accelerated
production of chemokines in HL-60 cells.
J Biochem.
2004;
135
4517-24
- 18
Chang Y H, Lee S T, Lin W W.
Effects of cannabinoids on LPS-stimulated inflammatory mediator release from macrophages:
involvement of eicosanoids.
J Cell Biochem.
2001;
81
715-23
- 19
Gallily R, Breuer A, Mechoulam R.
2-Arachidonylglycerol, an endogenous cannabinoid, inhibits tumor necrosis factor-α
production in murine macrophages, and in mice.
Eur J Pharmacol.
2000;
406
R5-R7
- 20
Facchinetti F, Del Giudice E, Furegato S, Passerotto M, Leon A.
Cannabinoids ablate release of TNFα in rat microglial cells stimulated with lipopolysaccharide.
Glia.
2003;
41
161-8
- 21
Klegeris A, Bissonnette C J, McGeer P L.
Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands
of the cannabinoid-type CB2 receptor.
Br J Pharmacol.
2003;
139
775-86
- 22
Parolaro D, Massi P, Rubino T, Monti E.
Endocannabinoids in the immune system and cancer.
Prostaglandins Leukot Essent Fatty Acids.
2002;
66
319-32
- 23
Turner R B.
The treatment of rhinovirus infections: progress and potential.
Antiviral Res.
2001;
49
1-14
- 24 Woelkart K, Koidl C, Grisold A, Gangemi J D, Turner R B, Marth E, Bauer R. Bioavailability
and pharmacokinetics of alkamides from the roots of Echinacea angustifolia in humans. J Clin Pharmacol 2005 45: 683-9
Rudolf Bauer
Institute of Pharmaceutical Sciences
Department of Pharmacognosy
Karl-Franzens-University Graz
Universitätsplatz 4/I
8010 Graz
Austria
Telefon: +43-316-380-8700
Fax: +43-316-380-9860
eMail: rudolf.bauer@uni-graz.at